Antiviral compounds in the pipeline to tackle H1N1 influenza infection

Drugs of the Future

Volumn 35, Issue 5, 2010, Pages 385-392

  Beigel, John H ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; ASD 890; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CS 8958; DAS 181; FAVIPIRAVIR; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INFLUENZA VACCINE; LANINAMIVIR; NITAZOXANIDE; OSELTAMIVIR; PERAMIVIR; PLACEBO; R 125489; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ANTIVIRAL RESISTANCE; AVIAN INFLUENZA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONVALESCENT PLASMA; COUGHING; DIARRHEA; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H5N1); MONOTHERAPY; NONHUMAN; PLASMA; REVIEW; SEASONAL INFLUENZA; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION; VIRUS REPLICATION;

EID: 77955447364     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.05.1487081     Document Type: Review

References (77)

1. World Health Organization. Pandemic (H1N1) 2009 - update 99. Accessed April 13, 2010 at http://www.who.int/csr/don/2010-05-07/en/index.html.
2. Monto, A.S. Vaccines and antiviral drugs in pandemic preparedness. Emerging Infect Dis 2006, 12(1): 55-60.
3. Moscona, A. Oseltamivir resistance - Disabling our influenza defenses. N Engl J Med 2005, 353(25): 2633-6.
4. High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2006, 55(2): 44-6.
5. Update: Influenza activity - United States, September 28-November 29, 2008. MMWR Morb Mortal Wkly Rep 2008, 57(49): 1329-32.
6. Update: Drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(16): 433-5.
7. Memoli, M.J., Hrabal, R.J., Hassantoufighi, A., Eichelberger, M.C., Taubenberger, J.K. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010, 50(9): 1252-5.
8. Mayburd, A.L. Influenza antiviral therapeutics. Recent Pat Antiinfect Drug Discov 2010, 5(1): 64-75.
9. Nicholson, K.G., Aoki, F.Y., Osterhaus, A.D. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: A randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355(9218): 1845-50.
10. Treanor, J.J., Hayden, F.G., Vrooman, P.S. et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283(8): 1016-24.
11. Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001, 45(10): 2723-32.
12. Yen, H.-L., Monto, A.S., Webster, R.G., Govorkova, E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005, 192(4): 665-72.
13. Massarella, J.W., He, G.Z., Dorr, A., Nieforth, K., Ward, P., Brown, A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol 2000, 40(8): 836-43.
14. Galegov, G.A., Pushkarskaya, N.L., Obrosova-Serova, N.P., Zhdanov, V.M. Combined action of ribovirin and rimantadine in experimental myxovirus infection. Experientia 1977, 33(7): 905-6.
15. Ilyushina, N.A., Hay, A., Yilmaz, N., Boon, A.C.M., Webster, R.G., Govorkova, E.A. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 2008, 52(11): 3889-97.
16. Smee, D.F., Hurst, B.L., Wong, M.-H., Bailey, K.W., Morrey, J.D. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 2009, 53(5): 2120-8.
17. Nguyen, J.T., Hoopes, J.D., Le, M.H. et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5(2): e9332.
18. Hayden, F.G., Douglas, R.G., Simons, R. Enhancement of activity against influenza viruses by combinations of antiviral agents. Antimicrob Agents Chemother 1980, 18(4): 536-41.
19. Govorkova, E.A., Fang, H.-B., Tan, M., Webster, R.G. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 2004, 48(12): 4855-63.
20. Smee, D.F., Bailey, K.W., Morrison, A.C., Sidwell, R.W. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002, 48(2): 88-93.
21. Smee, D.F., Hurst, B.L., Wong, M.H., Bailey, K.W., Tarbet, E.B., Morrey, J.D., Furuta, Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010, 54(1): 126-33.
22. Ilyushina, N.A., Hoffmann, E., Salomon, R., Webster, R.G., Govorkova, E.A. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice. Antivir Ther 2007, 12(3): 363-70.
23. Galabov, A.S., Simeonova, L., Gegova, G. Rimantadine and oseltamivir demonstrate synergistic combination effect in an experimental infection with type A (H3N2) influenza virus in mice. Antivir Chem Chemother 2006, 17(5): 251-8.
24. Leneva, I.A., Roberts, N., Govorkova, E.A., Goloubeva, O.G., Webster, R.G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000, 48(2): 101-15.
25. Smee, D.F., Huffman, J.H., Morrison, A.C., Barnard, D.L., Sidwell, R.W. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001, 45(3): 743-8.
26. Smee, D.F., Wong, M.-H., Bailey, K.W., Sidwell, RW. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother 2006, 17(4): 185-92.
27. Ilyushina, N.A., Bovin, N.V., Webster, R.G., Govorkova, E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006, 70(3): 121-31.
28. Nguyen, J.T., Hoopes, J.D., Smee, D.F. et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009, 53(10): 4115-26.
29. Ison, M.G., Gnann, J.W., Nagy-Agren, S. et al., NAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003, 8(3): 183-90.
30. Raether, W., Hanel, H. Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 2003, 90(Suppl. 1): S19-39.
31. Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009, 284(43): 29798-808.
32. Meindl, P., Bodo, G., Palese, P., Schulman, J., Tuppy, H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1974, 58(2): 457-63.
33. von Itzstein, M., Wu, W.Y., Kok, G.B. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363(6428): 418-23.
34. Cass, L.M., Efthymiopoulos, C., Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999, 36(Suppl. 1): 1-11.
35. Hayden, F.G., Osterhaus, A.D., Treanor, J.J. et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997, 337(13): 874-80.
36. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998, 352(9144): 1877-81.
37. Gubareva, L.V., McCullers, J.A., Bethell, R.C., Webster, R.G. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998, 178(6): 1592-6.
38. de Jong, M.D., Simmons, C.P., Thanh, T.T. et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12(10): 1203-7.
39. Fritz, R.S., Hayden, F.G., Calfee, D.P. et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: Results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999, 180(3): 586-93.
40. Luke, T.C., Casadevall, A., Watowich, S.J., Hoffman, S.L., Beigel, J.H., Burgess, T.H. Hark back: Passive immunotherapy for influenza and other serious infections. Crit Care Med 2010, 38(4, Suppl.): e66-73.
41. Lu, J., Guo, Z., Pan, X. et al. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Respir Res 2006, 7: 43.
42. Sandbulte, M.R., Jimenez, G.S., Boon, A.C.M., Smith, L.R., Treanor, J.J., Webby, R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 2007, 4(2): e59.
43. Skriabina, E.A. [Specific therapy of influenza.]. Vestn Akad Med Nauk SSSR 1954, 4: 34-9.
44. Tushinskii, M.D., Skriabina, E.A. [Specific serotherapy of influenza.]. Sov Med 1955, 19(1): 13-9.
45. Berezina, A.I. [Experience in treating influenza with dry anti-influenza serum of Smorodintsev; preliminary report.]. Sov Med 1956, 20(1): 67-8.
46. Ritova, V.V., Zhdanov, V.M. [On the method of serotherapy of influenza.]. Klin Med (Mosk) 1962, 40: 117-22.
47. Bilda, I., Schreiter, G. [Hyperimmune serotherapy of viral influenza.]. Kinderarztl Prax 1963, 31: 341-8.
48. Stavskaia, V.V., Ignateva, N.A. [On the treatment of influenza and influenzal pneumonia.]. Klin Med (Mosk) 1963, 41: 69-75.
49. Selivanov, A.A., Morozenko, M.A., Kallas, E.V., Nikitin, M.I., Nikitina, L.E. [Experimental for achievement of therapeutic sera against respiratory infections from immunized donors]. Vrach Delo 1967, 1: 104-6.
50. Luke, T.C., Kilbane, E.M., Jackson, J.L., Hoffman, S.L. Meta-analysis: Convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment? Ann Intern Med 2006, 145(8): 599-609.
51. Babu, Y.S., Chand, P., Bantia, S. et al. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000, 43(19): 3482-6.
52. Drusano, G.L., Preston, S.L., Smee, D., Bush, K., Bailey, K., Sidwell, R.W. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001, 45(7): 2115-8.
53. Sweet, C., Jakeman, K.J., Bush, K. et al. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 2002, 46(4): 996-1004.
54. Barroso, L., Treanor, J., Gubareva, L., Hayden, F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: Randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005, 10(8): 901-10.
55. FDA. Emergency Use Authorization of Peramivir IV. Fact Sheet for Health Care Providers. November 19, 2009.
56. Birnkrant, D., Cox, E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009, 361(23): 2204-7.
57. Yamashita, M., Tomozawa, T., Kakuta, M., Tokumitsu, A., Nasu, H., Kubo, S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009, 53(1): 186-92.
58. Ishizuka, H., Yoshiba, S., Okabe, H., Yoshihara, K. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J Clin Pharmacol 2010, Epub ahead of print.
59. Koyama, K., Takahashi, M., Oitate, M., Nakai, N., Takakusa, H., Miura, S., Okazaki, O. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract. Antimicrob Agents Chemother 2009, 53(11): 4845-51.
60. Positive top line results from phase III study (MARVEL) of anti-influenza virus agent CS-8958. Daiichi Sankyo Co. News Release, Aug 10, 2009. Accessed April 13, 2010 at http://www.daiichisankyo.com/news/detail/003245.html.
61. Malakhov, M.P., Aschenbrenner, L.M., Smee, D.F. et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother 2006, 50(4): 1470-9.
62. Triana-Baltzer, G.B., Gubareva, L.V., Nicholis, J.M. et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009, 4(11): e7788.
63. Chan, R.W.Y., Chan, M.C.W., Wong, A.C.N. et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 2009, 53(9): 3935-41.
64. Triana-Baltzer, G.B., Gubareva, L.V., Klimov, A.I. et al. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One 2009, 4(11): e7838.
65. Hedlund, M., Aschenbrenner, L.M., Jensen, K., Larson, J.L., Fang, F. Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection. J Infect Dis 2010, 201(7): 1007-15.
66. Furuta, Y., Takahashi, K., Kuno-Maekawa, M. et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005, 49(3): 981-6.
67. Furuta, Y., Takahashi, K., Fukuda, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002, 46(4): 977-81.
68. Takahashi, K., Furuta, Y., Fukuda, Y. et al. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 2003, 14(5): 235-41.
69. Gowen, B.B., Wong, M.-H., Jung, K.-H. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007, 51(9): 3168-76.
70. Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smee, D.F., Christensen, A.J., Furuta, Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res 2008, 80(3): 377-9.
71. Julander, J.G., Smee, D.F., Morrey, J.D., Furuta, Y. Effect of T-705 treatment on Western equine encephalitis in a mouse model. Antiviral Res 2009, 82(3): 169-71.
72. Jacobs, B., Langland, J. When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded RNA. Virology 1996, 219(2): 339-49.
73. Zhu, X., Nishimura, F., Sasaki, K. et al. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Translation Med 2007, 5: 10.
74. Huang, C.C., Duffy, K.E., San Mateo, L.R., Amegadzie, B.Y., Sarisky, R.T., Mbow, M.L. A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells. Physiol Genomics 2006, 26(2): 125-33.
75. Wong, J.P., Saravolac, E.G., Sabuda, D., Levy, H.B., Kende, M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother 1995, 39(11): 2574-6.
76. Barnard, D.L., Day, C.W., Bailey, K. et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006, 17(5): 275-84.
77. Baron, S., Salazar, A., Pestka, S., Poast, J., Clark, B. Smallpox model: Protection by IFN and poly I:CLC despite evasive mechanisms. Int Conf Antiviral Res 2003.